Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
Thank you moonrocket. To be honest as long as my decisions are always made with the best of intentions (in life as well as stocks) I can live with whatever unfolds. I too believe this will do well but I went in a bit heavy and didn't mitigate risk properly
Wressmycase I knew it was a pump and dump just thought I would be able to get out with a profit after a day, instead I'm here holding the baby while the other half is out getting chatted up my some Latino fella lol!
So I thought I would share a bit of much needed honesty on this board. I, like a few people on here im sure are relatively new to trading. I started learning about trading with the same goal in mind as everyone else: to become wealthier so I can better my life and my family's. In the past 6 months I have done reasonably well and learned a lot and I enjoy researching the stocks and gaining knowledge. Like a few others on here I saw what happened with knb and a quick Google of "next cannabis ipo" led me to cbx. I was lucky enough to get £1k at 5p and was so sure the hype and demand for this share would see it eclipse knb's results. On Friday morning I had another £19k to throw at it but hesitated due to the opening price so I put my phone down. Another hour later and it was 27p so fomo kicked in and I pressed buy with that 19k. My average after the ipo shares went in is now 20p and I'm 8k down. I've spent this week depressed and angry at myself for going in with money I can't afford to lose but in hindsight it could have easily gone the other way. The lesson I have learned from these last few days far outweighs the money I'm down and I'm sure cbx will come good next year. My humble goal with all this is to provide the best life possible for my daughter and girlfriend and people need to remember when ****ging each other off to show empathy and humility towards each other. We are all in this for the same reasons and I wish everyone the best of luck with all their investment decisions!
Who enters a trade on a Friday and exits on a Monday because they haven't bagged? Everyone who was looking for a knb repeat would have seen that it took a couple days for that rise. Clearly price manipulation as both the 1m and 2m buys were at 14.5p
The ipo was 13x oversubscribed so in theory alot of the money that was refunded by primary bid was either put elsewhere or reinvested back in cbx friday/today. So how is the price going down when the demand is high? I know there was a HUGE sell order today too and wonder where the hell that came from because nobody from ipo had that volume and everyone else is supposedly locked in?
My heart can't take this anymore lol. Just shoot up to 50p and let me go
Having been born in America and gone back numerous times over the years one thing I know for sure is..... any drug that doesn't require those fat b******* to hop on their mobility scooter and burn precious calories twisting a throttle down columns avenue is a certified WINNER!!!
Wouldn't be the first time a purring pussy has affected my finances haha
Thanks hereshopin I wasn't aware of that I assumed i would get all i asked for....
Just sold my bitcoin and reinvested 25k In cellular goods. He who dares wins......or cries under a cold shower hahaha
Just bought in at 39p. Hope I haven't missed the boat!
He enjoys long walks along the cornish coastline with his black labrador named waffle. His favourite book is 50 shades of grey and by the tender age of 15 he had successfully set up a multi million pound hummus manufacturing business
The best news outlet??? Looool. 2 words. Jimmy. Saville
Synairgen (Buy, TP: 990p) World-class asset to treat SARS-CoV-2
Synairgen has developed an inhaled version of interferon-beta (SNG001), that has recently proven highly effective for the treatment of SARS-CoV-2 (COVID-19) in a gold-standard, placebo-controlled Phase 2 study conducted across leading respiratory centres in the UK. The drug is widely known to enhance the innate immune response, which is the body's first line of defense against viruses, and is unique in being delivered directly into the lungs, where respiratory viruses initally take hold.
Subject to funding we expect a pivotal trial to start before the end of the year, and if the Phase 2 data is replicated in a larger Phase 3 study, SNG001 would be the most effective treatment for SARS-CoV-2 with future potential to treat various seasonal, endemic, and pandemic threats.
We initiate coverage with a Buy rating and 990p price target (6x upside) derived from a base (70%)/bear (30%) scenario analysis, which in our view represents a very compelling risk/reward proposition.
Download World-class asset to treat SARS-CoV-2
(36 pages)
Prospects have been transformed: The ongoing SARS-CoV-2 pandemic has demonstrated the threat posed by respiratory viruses. In a matter of months, capabilities have evolved to be able to test for, track and isolate infected patients to protect the vulnerable, yet numbers of cases, hospitalisations and sadly deaths, are still rising. We expect this capability will be retained, and that a therapeutic market and infrastructure for identifying and treating SARS-CoV-2 (and other respiratory viruses) has been rapidly created, that could be worth $20bn/year, a fraction of the costs of global lockdown.
Innately attractive: The innate immune response is known to weaken with age and illness (Source: WHO). The elderly and those with underlying conditions are the most vulnerable to SARS-CoV-2. SNG001 has been shown to activate, enhance and extend the innate, antiviral defense as measured using biomarkers in these patients. Synairgen's drug has previously been shown to be effective against SARS-1 and MERS, and based on Phase 2 data appears more effective than Gilead's Remdesivir. Insights from industry players, clinicians and KOLs support our views.
Compelling risk/reward: We detail the risks facing Synairgen throughout this note, but given the strong data in Phase 2, we place the chance of Phase 3 success at 70%, slightly above the industry average. The question then becomes what value can be placed on a drug that treats the vulnerable and could enable a return to the old normal? Our Bull case extends to £50/sh based on the valuations of Moderna/BioNTech with a need for SNG001 whether or not the vaccines prove successful.
Yet a successful investor can get nine women pregnant in one month......
Listen fellas, we can chew the fat on all sorts of outcomes but as someone who has a decent amount on 3 horses, sng, pre and he1 i can categorically say im a millionaire in 2.5yrs so join me for a pint in 6 months once sng gets rid of covid
In other words, " if phase 3 results equal or surpass phase 2's the usa will be unzipping my chinos Katie and your more than welcome to board the sng rocket". ??
The 2 things that stood out in todays proactive interview was the comment about ' good conversations' with big pharma and the carefully worded comment about working with governments 'cough cough'
So thats what the guy in boots was doing to me......